Back to search results

Intermittent Fasting for Non-Alcoholic Fatty Liver Disease (NAFLD)

This study is looking at whether a special diet called time-restricted, intermittent fasting can help adults with non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where too much fat builds up in your liver. This study focuses on people who have NAFLD but are not obese (BMI under 30kg/m2), sometimes called "lean NAFLD." You might be able to join if you are 18 or older, have a BMI between 23-30kg/m2, and have a confirmed diagnosis of NAFLD. Researchers will measure your liver fat content at the beginning and after 6 weeks to see if the diet makes a difference. The study plans to enroll 25 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention (time-restricted, intermittent fasting). It plans to enroll 25 participants.
What's involved
Participants will follow a special diet for 6 weeks. Liver fat content will be measured at the start and end of this period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 weeks, with liver fat content measured at the end of this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04899102

Intermittent Fasting for NAFLD in Adults

Recruiting
NAAges 18+InterventionalTreatment
Massachusetts General Hospital
~25 participants
Updated 2025-12-18 on ClinicalTrials.gov
What's tested:Time-Restricted, Intermittent Fasting

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Liver Fat Content
Measured over change from baseline to 6 weeks

Conditions

Fatty Liver
Intermittent Fasting
Fatty Liver, Nonalcoholic
Non-Alcoholic Fatty Liver Disease
Liver Fat

Explore related trials

Nonalcoholic Fatty Liver Disease

NCT04899102

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kathleen Corey, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Kathleen E Corey, MD/MPH
[email protected]
6177265925
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Grade \>=1 steatosis on clinical liver biopsy; OR
Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound) 5. Liver fat fraction ≥10% on H-MRS performed during the screening period 6. Hepatitis C antibody and Hepatitis B surface antigen negative at screening

What this trial measures

  • Liver Fat Contentchange from baseline to 6 weeks

    Liver Fat Content as measured by hydrogen-magnetic resonance spectroscopy (H-MRS)